Yasir A. Qazi

Rethinking Proteinuria: Resolution of Donor Derived EXT2-Associated Membranous Nephropathy Following Renal Transplantation.

Journal: Case reports in transplantation

Published: December 26, 2025

Response to comment on: Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: October 21, 2025

Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: December 30, 2024

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation.

Journal: Annals of transplantation

Published: July 02, 2021

Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management.

Journal: Transplantation proceedings

Published: June 10, 2021

Transplant administration-A survey of the roles and responsibilities of kidney and pancreas medical directors of US transplant centers.

Journal: Clinical transplantation

Published: January 25, 2021

Liver Transplantation in Patients with Sickle Cell Disease in the United States.

Journal: The Journal of surgical research

Published: January 07, 2020

High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: September 14, 2019

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: December 26, 2018

Rethinking Proteinuria: Resolution of Donor Derived EXT2-Associated Membranous Nephropathy Following Renal Transplantation.

Rethinking Proteinuria: Resolution of Donor Derived EXT2-Associated Membranous Nephropathy Following Renal Transplantation.

Response to comment on: Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study.

Response to comment on: Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study.

Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study.

Associations between donor-derived cell-free DNA dynamics and clinical outcomes after kidney allograft rejection: A prospective, multicenter study.

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation.

Clinical Rationale for a Routine Testing Schedule Using Donor-Derived Cell-Free DNA After Kidney Transplantation.

Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management.

Incorporation of Donor-derived Cell-free DNA Into Clinical Practice for Renal Allograft Management.

Transplant administration-A survey of the roles and responsibilities of kidney and pancreas medical directors of US transplant centers.

Transplant administration-A survey of the roles and responsibilities of kidney and pancreas medical directors of US transplant centers.

Liver Transplantation in Patients with Sickle Cell Disease in the United States.

Liver Transplantation in Patients with Sickle Cell Disease in the United States.

High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.

High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury.

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.

Delayed graft function in kidney transplantation.

Delayed graft function in kidney transplantation.

Marginal kidney transplantation: the road less traveled.

Marginal kidney transplantation: the road less traveled.

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.

Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.